InspireMD, Inc. (NYSEMKT:NSPR) Files An 8-K Other Events
Item 8.01 Other Events.
On April 5, 2017, InspireMD, Inc. (the Company) announced the
listing of Series B Warrants on the NYSE MKT beginning at the
market open on April 10, 2017. A copy of the press release is
attached as Exhibit 99.1 to this Current Report on Form 8-K and
is hereby incorporated by reference herein.
On April 6, 2017, the Company announced entering into a
distribution agreement with Angiocare B.V. for distribution of
CGuardTM EPS in the Netherlands. A copy of the press
release is attached as Exhibit 99.2 to this Current Report on
Form 8-K and is hereby incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit Number | Description | |
| 99.1 | Press release dated April 5, 2017 | |
| 99.2 | Press release dated April 6, 2017 |
About InspireMD, Inc. (NYSEMKT:NSPR)
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device. InspireMD, Inc. (NYSEMKT:NSPR) Recent Trading Information
InspireMD, Inc. (NYSEMKT:NSPR) closed its last trading session down -0.050 at 0.780 with 745,606 shares trading hands.
